Jill Feldman: Exciting news for the EGFR lung cancer community
Luis E. Raez, Medical Director at Memorial Cancer Institute, shared a post by Jill Feldman on X, adding:
“We have now 2 front line options amivantamab and lazertinib and chemotherapy and osi (FLAURA2) to enhance PFS in new patients with EGFR tumors we should consider them instead of osimertinib alone no need to wait for survival data.”
Quoting Jill Feldman’s post:
“Exciting news for the EGFR lung cancer community!
The FDA has approved amivantanab and lazertinib as a first-line therapy for EGFR NSCLC!
This new option brings promising PFS benefits from the MARIPOSA study to more patients—something we’ve needed for far too long.
Remember, more options mean more hope, but they also mean oncologists need to thoroughly discuss these choices with us.
And let’s not forget the importance of addressing dermatologic side effects right from the start.
More choices is equal to More hope!”
Additional information.
Source: Luis E. Raez/X and Jill Feldman/X